TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04471831

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation exercise protocol
Description: The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise protocol
Description: The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions.
Study: NCT02748889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Experimental biologic
Study: NCT02434757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
Study: NCT03673059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTC Eczema Moisturizer Regimen
Description: Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Moisturizer Regimen
Description: Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
Study: NCT02046928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A6
Description: A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
Study: NCT00731159

Intervention type: BIOLOGICAL
Intervention: sperm capacitation
Description: sperm capacitation measured at Bar Ilan University

Intervention type: OTHER
Intervention: biologic
Description: sperm synthesis of G-actine to F-actine

Intervention type: OTHER
Intervention: sperm capacitation
Description: sperm synthesis of G-actine to F-actine
Study: NCT03110666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous concentrated bone marrow aspirate
Description: Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
Study: NCT03050593

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan, Echo scan

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan, Echo scan

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan, Echo scan
Study: NCT01474226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Crystalline Lysine Amino Acid Mix
Description: crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cooked Rice containing Lysine
Description: Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
Study: NCT04042532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta-burst stimulation (TBS)
Description: We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta-burst stimulation (TBS)
Description: We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
Study: NCT04251065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade \> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days.
Study: NCT00417274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine
Description: 100 mg daily
Study: NCT00553540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Back supports
Description: The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
Study: NCT03144687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib self-administered orally once daily .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib self-administered orally once daily .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
Study: NCT03633747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
Study: NCT03854747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spinal stabilization exercise
Description: The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
Study: NCT05364567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
Study: NCT01346631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paleolithic diet
Description: The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
Study: NCT02597335

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spectro-MRI
Description: Spectro-MRI for D-2HG detection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dosage of free circulating plasmatic DNA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dosage of D-2HG in the urine
Study: NCT02567760

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP1
Description: Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive Placebo drink after meal for 8 weeks.
Study: NCT01004887

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study: NCT00894400

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: catheter ablation using radiofrequency energy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation using radiofrequency energy
Study: NCT04318106

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Precision tinted spectacle lenses
Description: Precision tinted spectacles lenses (Cerium Technologies TM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision tinted spectacle lenses
Description: Precision tinted spectacles lenses (Cerium Technologies TM)
Study: NCT01027052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hamburger meat patty with salt
Description: hamburger meat cooked with salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamburger meat patty with spice blend
Description: hamburger meat cooked with spice mixture
Study: NCT03572647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eritromax
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Study: NCT03997175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodiversity powder
Description: Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sand that looks like intervention sand but does not have high biodiversity
Study: NCT00540462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Study: NCT00429013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Display Unit
Description: lingual electric stimulation
Study: NCT04226989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-RD06
Description: CT-RD06 cell injection by intravenous infusion
Study: NCT01619189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epithelial stem cells cultured
Description: transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of cultured cells
Description: transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
Study: NCT02747823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT124
Description: 1 mg/kg IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU Sourced Avastin®
Description: 1 mg/kg IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Sourced Avastin®
Description: 1 mg/kg IV infusion
Study: NCT01225653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost
Description: Topical application
Study: NCT00004139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01376453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation sessions will be daily, Monday through Friday, except for holidays.
Study: NCT04315753

Intervention type: OTHER
Intervention: LDCT (Low Dose CT)
Description: validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
Study: NCT01997905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip LAA Exclusion Device
Study: NCT02259660

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength training
Description: Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham respiratory muscle strength training
Description: The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
Study: NCT03416322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange
Description: Infusion and remove water during inertion and withdrawal of colonoscope
Study: NCT02354820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence Based Constipation Reminders
Study: NCT04078971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: Subjects in this intervention will follow a normal western diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Subjects in this group will follow a low carbohydrate ketogenic diet
Study: NCT01409239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Description: 24 hr IV insulin administered according to hospital guideline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: basal bolus insulin using carb counting technique and insulin analogues
Study: NCT02706405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT00640770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty
Description: balloon angioplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting stent
Description: Cypher Select+ Coronary or Infrapopliteal Stent
Study: NCT03081364

Intervention type: OTHER
Intervention: Initiate ACLS protocol if lethal arrythmia develops
Description: Cardiac Rhythm Management
Study: NCT03789175

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nicotinamide Riboside (NR)
Description: Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
Study: NCT03061422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: caries prevention chewing gum
Study: NCT02983890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dicloxacillin
Description: Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned
Study: NCT06609122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support.
Study: NCT03061422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xylitol with bicarbonate
Description: caries prevention chewing gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paraffin
Description: chewing gum
Study: NCT02292862

Intervention type: PROCEDURE
Intervention: Lymph node and blood sampling
Description: By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant.
Study: NCT00603525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Study: NCT02032589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-generation treatment
Description: self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks